The incidence of acute myeloid leukaemia (AML) increases with age and mortality exceeds 90% when diagnosed after age 65. Most cases arise without any detectable early symptoms and patients usually present with the acute complications of bone marrow failure 1 . The onset of such de novo AML cases is typically preceded by the accumulation of somatic mutations in preleukaemic haematopoietic stem and progenitor cells (HSPCs) that undergo clonal expansion 2,3 . However, recurrent AML mutations also accumulate in HSPCs during ageing of healthy individuals who do not develop AML, a phenomenon referred to as age-related clonal haematopoiesis (ARCH) 4-8 . Here we use deep sequencing to analyse genes that are recurrently mutated in AML to distinguish between individuals who have a high risk of developing AML and those with benign ARCH. We analysed peripheral blood cells from 95 individuals that were obtained on average 6.3 years before AML diagnosis (pre-AML group), together with 414 unselected age-and gendermatched individuals (control group). Pre-AML cases were distinct from controls and had more mutations per sample, higher variant allele frequencies, indicating greater clonal expansion, and showed enrichment of mutations in specific genes. Genetic parameters were used to derive a model that accurately predicted AML-free survival; this model was validated in an independent cohort of 29 pre-AML cases and 262 controls. Because AML is rare, we also developed an AML predictive model using a large electronic health record database that identified individuals at greater risk. Collectively our findings provide proof-of-concept that it is possible to discriminate ARCH from pre-AML many years before malignant transformation. This could in future enable earlier detection and monitoring, and may help to inform intervention.
Letter reSeArCH a prevalence that is in line with the largest studies of ARCH in the general population 4 (P < 2.2 × 10 −16 , two-sided Fisher's exact test; Extended Data Fig. 1 ).
The median number of ARCH-PD mutations per individual increased with age and was significantly higher in the pre-AML group relative to controls ( Fig. 1b and Supplementary Table 2 ). Furthermore, examination of ARCH-PD VAF distribution revealed significantly larger clones among the pre-AML cases (P = 1.2 × 10 −13 , twosided Wilcoxon rank-sum test; Fig. 1c ). To gain insight into clonal growth dynamics, we examined serially collected samples that were available for a subset of the validation cohort. We did not find significant differences in clonal expansion rates between pre-AML cases and controls (Extended Data Fig. 2a, b ), although this may in part reflect the shorter follow-up of pre-AML cases, small sample size and large variance in growth rates (Extended Data Fig. 2c ). The observed differences between pre-AML cases and controls may arise through cell-intrinsic or -extrinsic factors. Although these variables have not been adequately studied in ARCH, a number of observations in different contexts, such as aplasia, advanced age and after chemotherapy, have shown that increased clonal fitness is associated with distinct mutations depending on context [10] [11] [12] . Notably, mutations in splicing factor genes were significantly enriched among the pre-AML cases relative to the controls (odds ratio, 17.5; 95% confidence interval, 8.1-40.4; P = 5.2 × 10 −16 , two-sided Fisher's exact test) and were present in significantly younger individuals (median age 60.3 compared to 77.3 years, P = 1.7 × 10 −4 , two-sided Wilcoxon rank-sum test; Fig. 2a ). Previous work suggests that spliceosome mutations appear to confer a competitive advantage in the context of ageing 10 . Therefore, it is possible that the significantly higher prevalence of such clones in younger pre-AML cases may reflect extrinsic selection pressures rather than earlier mutation acquisition.
In line with previous reports 5, 6 , we found that DNMT3A and TET2 were the most commonly mutated genes in both groups (Fig. 2b) . We could not identify any canonical NPM1 mutations nor any FLT3internal tandem duplication mutations, consistent with these arising late in leukaemogenesis 10, 13 . Recurrent CEBPA mutations, which are implicated in around 10% of de novo AML 14 , were also absent, suggesting that driver events in this gene may also be late events in AML evolution. In order to quantify the effect of different mutations on the likelihood of progression to AML, we ranked ARCH-PD mutations based on the number of times that they have been reported in Catalogue of Somatic Mutations in Cancer (COSMIC) database among individuals with haematological malignancies 15 . We found that mutations that are highly recurrent in cancer specimens were more common in pre-AML cases than in controls with ARCH-PD, whereas driver events in the controls tended to affect loci that are less frequently mutated in haematological malignancies and occurred at significantly lower VAF (Fig. 2c, d) . Overall, these findings demonstrate notable differences in the mutational landscape of ARCH and pre-AML. Moreover, this work, in conjunction with recent insights into the origins of AML relapse 16 , suggests that AML progression typically occurs over many years through clonal evolution of preleukaemic HSPCs before acquisition of late mutations leads to overt malignant transformation. of specific recurrent AML mutations in healthy individuals at a young age is associated with progression to AML. a, Relative frequency of mutations in the indicated genes according to age group for pre-AML cases and controls. b, Proportion of pre-AML cases (red) and controls (blue) who had ARCH-PD mutations in recurrently mutated genes. *P < 0.05, Fisher's exact test with Bonferroni multiple testing correction. c, The cumulative frequency of recurrent AML mutations (reported in >5 specimens in COSMIC) in pre-AML cases and controls. ARCH-PD mutations are ranked from left to right along the x axis from low to high recurrence. d, VAF of recurrent mutations in pre-AML cases and controls. Low, intermediate and highly recurrent COSMIC mutations are defined as those reported in 5-19 samples, 20-300 samples and >300 samples, respectively. Box plots indicate median, first and third quartiles and 1.5× interquartile range. *P < 0.05, two-sided Wilcoxon rank-sum test with Bonferroni multiple testing correction. All panels show data for n = 800 unique individuals.
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On the basis of these findings, we next developed an approach to quantify the relative contributions of driver mutations and clone sizes to the risk of progressing to AML. We tested different regularised logistic and Cox proportional hazards regression approaches, which achieved similar performance in both the discovery cohort (concordance (C) = 0.77 ± 0.03) and the validation cohort (C = 0.84 ± 0.05; Extended Data Figs. 3, 4 and Supplementary Table 3 ). Models that were only trained on data from the discovery or validation cohort had similar coefficients (Fig. 3a ). We therefore combined the datasets for a more accurate analysis of the contributions of mutations in individual genes to risk (C = 0.77 ± 0.05; area under curve, 0.79; Supplementary  Table 3 ). Quantitatively, we found that driver mutations in most genes conferred an approximately twofold increased risk of developing AML per 5% increase in clone size ( Fig. 3a and Supplementary Table 3 ). Notable exceptions to this trend are the most frequently mutated ARCH genes, DNMT3A and TET2, which confer a lower risk of progression to AML (Fig. 3a, b and Supplementary Table 3 ). By contrast, a larger effect size was apparent for TP53 (hazard ratio, 12.5; 95% confidence interval, 5.0-160.5) and U2AF1 (hazard ratio, 7.9; 95% confidence interval, 4.1-192.2) mutations ( Fig. 3a, b ). However, we note that other ARCH-PD genes, such as SRSF2, can contribute a similar relative risk owing to their presence at a higher VAF in pre-AML cases ( Fig. 3a , Extended Data Fig. 5a and Supplementary Note). Of note, mutations in TP53 and spliceosome genes (including U2AF1) are also associated with a poorer prognosis in AML 14 . Because the effect of each ARCH-PD mutation is deleterious and the effect of multiple mutations that are present in the same individual is multiplicative, a higher number of mutations is predicted to increase the risk of progression to AML (Fig. 3c) . Similarly, the size of the largest driver clone was also strongly associated with the risk of progression to AML, in agreement with the risk of individual mutations generally being proportional to VAF ( Fig. 3c ). Collectively, although the VAF and the number of mutations confer much of the predictive value, this model does demonstrate distinct gene-level risk factors, and is able to quantify the cumulative impact of multiple mutations and clonal size on the likelihood of progression to AML. Although our predictive model performs well in identifying those at risk of developing AML in our experimental cohorts, AML incidence rates in the general population are low (4:100,000) 1 , and thus millions of individuals would need to be screened to identify the few pre-AML cases, with many false positives. We therefore sought to determine whether routinely available clinical information could improve prediction accuracy or identify a high-risk population for targeted genetic screening. We first analysed complete blood count and biochemistry data that were available for 37 of the pre-AML cases and 262 controls. As reported previously 5,10,17 , ARCH-PD was overwhelmingly associated with normal blood counts and this was also the case for pre-AML cases, indicating that these did not represent undiagnosed myelodysplastic syndrome 18 . We identified a significant association between higher red blood cell distribution width (RDW) and risk of progression to AML (P = 0.0016, Wald test with Bonferroni multiple-testing correction, Fig. 3d ). Although traditionally used in the evaluation of anaemia, raised RDW has been correlated with inflammation, ineffective erythropoiesis, cardiovascular disease and adverse outcomes in several inflammatory and malignant conditions 19 . The correlation between RDW and risk of AML development remained highly significant when controls without ARCH-PD were excluded Purple, orange and green circles indicate hazard ratios for the discovery (DC), validation (VC) and combined cohort, respectively. The horizontal lines denote 95% confidence intervals for the combined cohort. For each gene, the indicated hazard ratio applies to the 10-year risk of AML development conferred by each 5% increase in mutation VAF. The green vertical line indicates the mean hazard ratio across all genes. The hazard ratio for RUNX1 must be interpreted with caution owing to the relatively high prevalence of deleterious germline variants in this gene, which may not be readily distinguishable from somatic mutations in unmatched sequencing assays (see Methods). The proportion of individuals with mutations in each gene and the average VAF are indicated to the right of the forest plot; red and blue circles represent pre-AML cases and controls, respectively, with circle sizes scaled to reflect mutation frequency and VAF. b-d, Kaplan-Meier curves of AML-free survival, defined as the time between sample collection and AML diagnosis, death or last follow-up. Survival curves are stratified according to mutation status for selected genes (b), number of driver mutations per individual and largest clone detected (c) and RDW (d). Data for n = 796 unique individuals (a-c); n = 299 individuals for whom RDW measurements were available (d).
Letter reSeArCH from the analysis (P = 3.5 × 10 −6 , Wald test with Bonferroni multiple testing correction; Extended Data Fig. 5b ). Higher RDW has previously been associated with ARCH and overall mortality 5 , but has never been shown to distinguish ARCH from pre-leukaemia. In order to verify RDW as a predictive factor and determine whether additional clinical parameters are associated with risk of AML development, we studied the Clalit database 20 , which contains electronic health records that include an average of 3.45 million individuals per year and data that were collected over a 15-year period 21 . We identified 875 cases with AML using stringent criteria based on diagnostic codes and treatment records (Extended Data Fig. 6 and Supplementary Table 4 ). Analysis of RDW trends revealed significantly raised measurements several years before AML diagnosis relative to age and sex-matched controls ( Fig. 4a ). Additional parameters that correlated with risk of AML development included reductions in monocyte, platelet, red blood cell and white blood cell counts, albeit usually remaining above the thresholds for clinically relevant cytopenias 18 ( Fig. 4a and Extended Data Fig. 7 ). These findings suggest that evolving de novo AML may sometimes have a considerable prodrome with subtle but discernible clinical manifestations. We next applied a machine-learning approach to construct an AML prediction model based entirely on variables that are routinely documented in electronic health records (Extended Data Fig. 8 and Supplementary Table 4 ). This model was able to predict AML 6-12 months before diagnosis with a sensitivity of 25.7% and overall specificity of 98.2%. The model performed consistently across different age groups with an increased relative risk of 28 and 24 for males and females, respectively, between the age of 60 and 70 years ( Fig. 4b ).
To better understand which patients are most likely to be accurately classified by this model, we compared absolute laboratory values for true positives and false negatives. We found that 35.5% of false-negative predictions were for patients for whom infrequent blood count data were available (Extended Data Fig. 9 ). Some of the true-positive cases had mildly abnormal blood counts that would not initiate a diagnostic work-up ( Fig. 4c ), and cytopenias that would be compatible with undiagnosed myelodysplastic syndrome 18 were uncommon. Collectively, our findings provide new insights into the pre-clinical evolution of AML and support the hypothesis that individuals at high risk of AML development can be identified years before they develop overt disease. To this end, we present two distinct models for the prediction of de novo AML: one based on somatic point mutations and the other on routinely documented clinical information. We find that basic clinical and laboratory data can identify a high-risk subgroup 6-12 months before AML presentation, while genetic information can identify a substantial fraction of cases several years to more than a decade before diagnosis. By characterizing features that distinguish benign ARCH from pre-leukaemia, our models give valuable insights into leukaemogenesis. It is evident from the current study, together with our recent analysis of mutation acquisition from pre-leukaemic development through to relapse 16 , that long-term pre-leukaemic HSPCs frequently carry mutations and undergo considerable clonal expansion while retaining differentiation capacity for years before AML diagnosis. Furthermore, it is clear that some mutations, particularly those affecting TP53 and U2AF1, impart a relatively high risk of subsequent AML, whereas mutations in other genes, for example DNMT3A and TET2, confer a lesser risk of malignant transformation. Previous studies suggest that oncogenic mutations in TP53 and spliceosome genes confer little or no competitive advantage in the absence of particular selective pressures 11, 22 , indicating that cell-extrinsic factors may be important determinants of clonal trajectory.
Cancer predictive models have enabled successful early detection and intervention programmes for several solid tumours [23] [24] [25] . However, screening tests are unavailable for the sub-clinical stages of most haematological malignancies. Our study provides proof-of-concept for the feasibility of early detection of healthy individuals at high risk 
Years before AML diagnosis Letter reSeArCH of developing AML, and is a first step in the design of future clinical studies to investigate the potential benefits of early interventions in this deadly disease. However, the infrequency of AML necessitates that future screening tests provide high sensitivity and specificity. Our findings suggest that basic clinical data may identify a higher risk population that might benefit from targeted genetic screening. Equally, combining clinical and genetic information in a single model and including structural driver events is likely to improve model accuracy further. Nevertheless, establishing the utility of such a tandem approach will require extensive clinical and genetic analysis on the same population cohort, in a prospective setting. Furthermore, ARCH is associated with several non-malignant conditions 4, 5 , and may have a causal role in cardiovascular disease 26, 27 . Therefore, genetic testing for ARCH may also prove useful in the management of common age-related diseases. Moreover, this study has broader implications for cancer screening and early intervention beyond AML. Advances in sequencing technologies have revealed a remarkable degree of somatic genetic diversity in normal ageing tissues, often characterized by the presence of clones that have canonical oncogenic mutations 28 . The degree to which clones at high risk of malignant transformation can be reliably distinguished from their indolent counterparts is an important biological question with compelling clinical ramifications. Understanding the selective pressures and cell-intrinsic mechanisms governing clonal fate is the next important step in developing strategies to predict and prevent progression to overt malignancy.
Online content
Any Methods, including any statements of data availability and Nature Research reporting summaries, along with any additional references and Source Data files, are available in the online version of the paper at https://doi.org/10.1038/s41586-018-0317-6
Letter reSeArCH MEthodS Data reporting. No statistical methods were used to predetermine sample size. The experiments were not randomized and the investigators were not blinded to allocation during experiments and outcome assessment. Study participants. Samples for both the discovery and validation cohort were obtained from participants in the EPIC study 29 . All relevant ethical regulations were followed. Written informed consent was obtained from all participants in accordance with the Declaration of Helsinki and protocols were approved by the relevant ethics committees (IARC Ethics Committee approval #14-31, the Weizmann Institute of Science Ethics board approval #60-1 and East of England-Cambridgeshire and Hertfordshire Research Ethics Committee reference number 98CN01). Patients with AML were identified based on the following ICD9 codes: 9861/3, 9860/3, 9801/3, 9866/3, 9891/3, 9867/3, 9874/3, 9840/3, 9872/3, 9895/3, 9873/3, which included only cases of de novo AML, and no secondary AML. All patients provided peripheral blood samples for which the buffy coat fractions were separated and aliquoted for long-term storage in liquid nitrogen before DNA extraction. Discovery cohort. In total, 509 DNA samples were collected from individuals upon enrolment into the EPIC study between 1993 and 1998 across 17 different centres 29 ( Supplementary Table 1 ). Altogether, 95 individuals who developed AML an average of 6.3 years (interquartile range (IQR) = 4.8 years) after the sample was collected were included in the pre-AML group. For the control group, 414 age-and gender-matched individuals were selected, as they did not develop any haematological disorders during the average follow-up period of 11.6 years (IQR = 2.1 years). The median age at recruitment was 56.7 years (range, 36.08-74.42). In order to minimize any possible demographic biases, an approximate 1:4.5 pre-AML to control ratio was maintained across the different centres. Validation cohort. Samples were obtained from individuals enrolled in the EPIC-Norfolk longitudinal cohort study between 1994 and 2010. Samples and clinical metadata were available from 37 patients with AML (of which 8 were already included in the discovery cohort) and 262 age-and gender-matched controls without a history of cancer or any haematological conditions. The average time between the first blood sampling and AML diagnosis was 10.5 years (IQR = 8.3 years). The average follow-up period for the control cohort was 17.5 years (IQR = 3.8). For 12 individuals in the pre-AML cohort, 2-3 blood specimens were available, taken a median of 3.4 years apart. Of the 262 controls, 141 had multiple blood samples available, spanning a median of 10.5 years. Blood counts and other clinical parameters were available for all study participants (Supplementary Table 1 ). Targeted sequencing. Discovery cohort sequencing. Targeted deep sequencing was performed using error-corrected sequencing as follows.
Shearing of genomic DNA, preparation of pre-capture sequencing libraries, hybridization-based enrichment, assessment of the libraries quality and enrichment following hybridization were performed as previously described 30 . In brief, 100 ng of genomic DNA was sheared before library construction (KAPA Hyper Prep Kit KK8504, Kapa Biosystems) with a Covaris E220 instrument using the recommended settings for 250-bp fragments. Following end repair and A-tailing, adaptor ligation was performed using 100-fold molar excess of Molecular Index Adaptor. Library clean-up was performed with Agencourt AMPure XP beads (Beckman-Coulter) and the ligated fragments were then amplified for eight cycles using 0.5 μM Illumina universal and indexing primers.
Targeted capture was carried out on pools containing three indexed libraries. Each pool of adaptor-ligated DNA was combined with 5 μl of 1 mg ml −1 Cot-I DNA (Invitrogen), and 1 nmol each of xGEN Universal Blocking Oligo, TS-p5, and xGen Universal Blocking Oligo, TS-p7 (8 nucleotides). The mixture was dried using a SpeedVac and then re-suspended in 1.1 μl water, 8.5 μl NimbleGen 2× hybridization buffer and 3.4 μl NimbleGen hybridization component A. The mixture was heat denatured at 95 °C for 10 min before addition of 4 μl of xGen Lockdown Probes (xGen AML Cancer Panel v.1.0, 3 pmol). Each pool was then hybridized at 47 °C for 72 h. Washing and recovery of the captured DNA was performed according to the manufacturer's specifications. In brief, 100 μl of clean streptavidin beads was added to each capture. Following separation and removal of the supernatant using a magnet, 200 μl 1× Stringent Wash Buffer was added and the reaction was incubated at 65 °C for 5 min. The supernatant containing unbound DNA was removed before repeating the high stringency wash one additional time. Then, the bound DNA was washed as follows: (1) 200 μl 1× Wash Buffer I and separation of the supernatants by magnetic separation; (2) 200 μl 1× Wash Buffer II after magnetic separation; (3) 200 μl 1× Wash Buffer III and removal of the supernatants using magnetic separation. The captured DNA on beads was resuspended in 40 μl of Nuclease-Free water before dividing the total volume into two PCR tubes and subjecting the libraries to 10 cycles of post-capture amplification (manufacturer-recommended conditions; Kapa Biosystems). Before sequencing, libraries were spiked with 2% PhiX. Validation cohort sequencing. Targeted sequencing was performed using a custom complementary RNA bait set (SureSelect, Agilent, ELID 0537771) designed complementary to all coding exons of 111 genes that have been implicated in myeloid leukaemogenesis (Extended Data Table 1 ). Genomic DNA was extracted from peripheral whole blood and sheared using the Covaris M220. Equimolar pools of 10 libraries were prepared and sequenced on the Illumina HiSeq 2000 using 75-bp paired-end sequencing as per Illumina and Agilent SureSelect protocols. Variant calling. Discovery cohort variant calling and error correction. The 126-bp paired-end reads sequencing data from the Illumina platform were converted to FASTQ format, the 2-bp molecular barcode information at each read of the pair was trimmed and was written in the reads' name. The thymine nucleotide required for ligation was removed from the sequences. Burrows-Wheeler aligner (BWA-mem) 31 was used for alignment of the processed FASTQ files to the reference hg19 genome, after realignment of insertions and deletions (indels) using GATK 32 . An in-house algorithm was written to collapse read families that share the same molecular barcode sequence, the left-most genomic position of where each read of the pair maps to the reference and the CIGAR string. Families that consisted of at least two reads were used to generate consensus reads and a consensus base was called when there was at least 70% agreement. When a consensus base was called, it was assigned with the maximum base quality score observed in its corresponding pre-collapsed reads. Furthermore, when possible, duplex reads 33 were generated from two consensus reads, from a singleton read and a consensus read, or from two singleton reads. For each sequenced sample, we generated two BAM files, called BAM1 and BAM2. BAM1 consisted of duplex reads, consensus reads and singleton reads, thereby including some error-corrected and non-error corrected reads, while still containing all the genomic information encoded in the data in the form of unique DNA molecules. BAM2 consisted of duplex reads and consensus reads but not singleton reads. Both files were then analysed to detect single nucleotide variants (SNVs) and small indels using Varscan2 34 . To further remove sequencing artefacts and improve sensitivity, we applied a two-step polishing statistical approach that models the error rate for each sequenced genomic position. For both steps, BAM1 was used and all samples except the sample that was investigated were included for error rate modelling. At step one, as previously described 30 , the error rates were modelled by fitting Weibull distribution curves to the non-reference allele fractions. SNVs with allele fractions that were statistically distinguishable from the background error rates (P = 0) were further analysed. At step 2, the coverage of the non-reference allele fractions was considered using linear line fitting that describes the negative correlation that exist between the log(non-reference allele fraction) and the corresponding log(coverage) values. This allowed us to estimate different error rates at different coverage depths. Because indel errors are rare and cannot be appropriately modelled by the same statistical framework, they were called using barcode-mediated error correction alone. At least 10 consensus reads, 5 supporting reads on the forward strand, 5 supporting reads on the reverse strand and 2 duplex reads were required to call an indel. Additional post-processing steps applied to data from both the discovery cohort and validation cohort are detailed in ' Additional post-processing filters applied to discovery and validation cohort data' . Variants were annotated using Annovar 35 . Validation cohort variant calling. Sequencing reads were aligned to the reference genome (GRCh37d5) using the Burrows-Wheeler aligner (BWA-aln) 31 . Unmapped reads, PCR duplicates and reads mapping to regions outside the target regions (merged exonic regions and 10 bp either side of each exon) were excluded from analysis. Sequencing depth at each base was assessed using Bedtools coverage v.2.24.0 36 .
Somatic SNVs were called using shearwater, an algorithm developed for detecting subclonal mutations in deep-sequencing experiments (https://github. com/gerstung-lab/deepSNV v.1.21.5) 37-39 considering only reads with minimum nucleotide and mapping quality of 25 and 40, respectively. This algorithm models the error rate at individual loci using information from multiple unrelated samples. Additionally, allele counts at the recurrent AML mutation hotspots listed in 'Curation of oncogenic variants' were generated using an in-house script (https:// github.com/cancerit/alleleCount) and manually inspected in the Jbrowse genome browser 40 . To further complement our SNV calling approach, we applied an extensively validated in-house version of CaVEMan v.1.11.2 (Cancer variants through expectation maximization) 41 . CaVEMan compares sequencing reads between study and nominated normal samples and uses a naive Bayesian model and expectation-maximization approach to calculate the probability of a somatic variant at each base (https://github.com/cancerit/CaVEMan).
Post-processing filters required that the following criteria were met for CaVEMan to call a somatic substitution. (1) If coverage of the mutant allele was less than 8, at least one mutant allele was detected in the first two-thirds of the read. (2) Less than 3% of the mutant alleles with base quality ≥15 were found in the nominated normal sample. The following additional post-processing criteria were applied to all SNV calls. (1) Minimum VAF = 0.5% with a minimum of five bidirectional calls reporting the mutant allele (with at least two reads in forward and reverse directions). (2) No indel called within a read length (75 bp) of the putative substitution.
Small indels were sought using two complementary bioinformatics approaches. First, an in-house version of Pindel v.2.2 42 (https://github.com/cancerit/cgpPindel) was applied. We additionally used the aforementioned deepSNV algorithm in order to increase sensitivity for indels present at low VAF. VAF correction was performed using an in-house script (https://github.com/cancerit/vafCorrect).
Post-processing filters required that the following criteria were met for a variant to be called. (1) A minimum of five reads supporting the variant with a minimum of two reads in each direction. For Pindel, the total read count was based on the union of the BWA and Pindel reads reporting the mutant allele. (2) VAF ≥ 0.5%. Mutations were annotated according to ENSEMBL v.58 using VAGrENT 43 for transcript and protein effects (https://github.com/cancerit/VAGrENT) and Annovar 35 for additional functional annotation. Additional post-processing filters applied to discovery and validation cohort data. The following variants were flagged for additional inspection for potential artefacts, germline contamination or index-jumping event. (1) Any mutant allele reported within 75 bp of another variant. (2) Any mutant allele with a population allele frequency >1 in 1,000 according to any of five large polymorphism databases (ExAC, 1000 Genomes Project, ESP6500, CG46 and Kaviar) that is not a canonical hotspot driver mutation with COSMIC recurrence >100. (3) Mutations that were present in >10% of the control cohort but not recurrent in COSMIC were flagged as potential germline variants or sequencing artefacts. (4) As artefactual indels tend to be recurrent, any indels occurring in >2 samples were flagged as for additional inspection. Curation of oncogenic variants. Putative oncogenic variants were identified according to evidence for functional relevance in AML as previously described and used to define ARCH-PD 14 .
Variants were annotated as likely driver events if they fulfilled any of the following criteria. (1) Truncating mutations (nonsense, essential splice site or frameshift indel) in the following genes implicated in AML pathogenesis by loss-of-function: NF1, DNMT3A, TET2, IKZF1, RAD21, WT1, KMT2D, SH2B3, TP53, CEBPA, ASXL1, RUNX1, BCOR, KDM6A, STAG2, PHF6 and KMT2C. (2) Truncating variants in CALR exon 9. (3) JAK2 V617F . (4) FLT3 internal tandem duplication. (5) Nonsynonymous variants at the following hotspot residues: CBL E366, L380, C384, C404, R420 and C396; DNMT3A R882; FLT3 D835; IDH1 R132; IDH2 R172 and R140; KIT W557, V559 and D816; KRAS A146, Q61, G13 and G12; MPL W515; NRAS Q61, G12 and G13; SF3B1 K700 and K666; SRSF2 P95; U2AF1 Q157, R156 and S34. (6) Non-synonymous variants reported at least 10 times in COSMIC with VAF <42% and population allele frequency <0.003. (7) Non-synonymous variants clustering within a functionally validated locus or within four amino acids of a hotspot variant with population allele frequency <0.003 and VAF <42%. (8) Non-synonymous variants reported in COSMIC >100 times with population allele frequency <0.003 regardless of VAF.
Our driver curation strategy inevitably runs a small risk of including germline variants in familial AML genes. We feel that in the real world, where a matched constitutional DNA sample would be unavailable, this is the best approach. Statistical analysis. All statistical analyses were performed in the R statistical programming environment. A two-sided Wilcoxon rank-sum test was used to assign significance level for differences in the median number of somatic mutations among the pre-AML and control groups, the median VAF of mutations among groups. and the age of individuals with spliceosome mutations. Fisher's exact test was used to assess the significance of differences in the prevalence of ARCH among the groups and spliceosome mutations in the pre-AML group. Predictive modelling. Cox proportional hazards model with random effects. We used a Cox proportional hazards regression to model AML progression-free survival as previously described 14, 38 . We used random effects for the Cox proportional hazards model in the CoxHD R package (http://github.com/gerstung-lab/CoxHD).
A key strength of this approach is the ability to include many variables in one model while shrinking estimated effects for parameters with weak support in the data, thus controlling for overfitting. We used weighting to minimize the biases introduced by the artificial case-control ratio 44,45 and calculated hazard ratios relative to the (approximate) true cumulative incidence of about 1-3/1,000 in the given age range over a follow up of 10-20 years. The observed driver mutation frequency and VAF in pre-AML cases closely resembled values expected based on the estimated risks, indicating that risk model and driver prevalence are well aligned (Extended Data Fig. 4) . Full details of model derivation and comparisons with alternative methods are included in the accompanying code (Supplementary Note, also available at https://github.com/gerstung-lab/preAML). In brief, variables comprised age, gender and the VAF of putative driver mutations (see 'Curation of oncogenic variants' for details of variant curation). We performed agnostic imputation of missing variables by mean and linear rescaling of gene variables by a power of 10 to a magnitude of 1. The model was first trained separately on the discovery cohort and validation cohort. For each of these two models, we evaluated the following measures of predictive accuracy before and after leave-one-out cross-validation (LOOCV): concordance (C) 46 and time-dependent area under the receiver-operating characteristic curve (AUC) 47 . The models trained on the validation and discovery cohorts were then cross-validated using the data from the other cohort. In view of the cross-validation results and close correlation between coefficients ( Supplementary Table 3) , we derived a model on the combined cohorts using both cohorts in order to achieve greater accuracy on the individual effects. Confidence intervals were calculated using 100 bootstrap samples. The coefficients and performance metrics for each iteration of the model are included in Supplementary Table 3 .
Concordance measures were obtained using the survConcordance() function implemented in the survival R package 45 . Dynamic AUC was calculated with AUC.uno() implemented in the survAUC package. Time-independent AUCs were calculated using the performance function implemented in the ROCR package. The expected incidence of AML was calculated from the UK office of national statistics, available at http://www.cancerresearchuk.org/health-professional/ cancer-statistics/statistics-by-cancer-type/leukaemia-aml/incidence. All-cause mortality data was obtained from the office of national statistics (https://www.ons. gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/lifeexpectancies/datasets/nationallifetablesunitedkingdomreferencetables). Ridge-regularized logistic regression. Using the same covariates as in 'Cox proportional hazards model with random effects' , we fitted a ridge-regularized logistic regression model to dichotomised outcome data. While logistic regression is a common choice for case-control analyses, a downside of this approach is the inability to explicitly use time-dependent covariates. The penalty parameter was chosen using LOOCV on the full cohort; this value was then used on the discovery cohort and validation cohort to yield the same scaling of coefficients. Confidence intervals were calculated using 100 bootstrap samples. Fitting was performed using the glmnet R package. AUC as the primary performance metric was calculated using the ROCR R package. Additional regression models. Two alternative predictive models were developed. Model 1 performs logistic-regression-based predictions using four types of features: gender, age at blood sampling, the sum of the VAFs ARCH-PD reported in COSMIC v.80 to be recurrent (at least two case reports in haematopoietic and lymphoid tissues) and somatic mutation burden of selected genes, where each gene was represented by the sum of the VAFs corresponding to ARCH-PD mutations in that gene. We measured the predictive performance of each gene via the AUC obtained in a fivefold cross-validation when using only the gene as a predictive feature, and only retained genes with AUC > 55% in the final model.
For model 2 we applied LASSO regression as implemented in the glmnet R package, while enabling LOOCV to fit a Cox regression model. A minimal subset of ARCH-PD variants was selected for which the respective weighted combined VAFs were highly predictive of AML development in the training set. Scores were calculated for each patient as a linear combination of VAF of mutations weighted by regression coefficients that were estimated from the training data. As most scores were zero in the training subset, non-zero scores were discretized to take on a value of 1 that corresponds to AML prediction. Models 1 and 2 were trained on the discovery cohort and tested for their association with AML development using the validation cohort data. Survival analysis was performed using the Kaplan-Meier and Cox proportional hazards models. Wald's test was used to evaluate the significance of hazard ratios. Logistic regression models were used with the positive predictive value metric to determine the ability of various mutations and other patient parameters to predict AML development. The rms R package was used for logistic regression analysis, and the pROC 1.8 R package was used for receiver-operating characteristic curve analysis. AML-predictive model based on electronic health records. Clalit database. The Clalit database includes information from patients covered by the Clalit health services in Israel 20 during the years 2002-2017. The Clalit training-set data, contains the electronic health records (EHR) of 3.45 million individuals per year on average. All data was anonymized through hashing of personal identifiers and addresses and randomization of dates by sampling a random number of weeks for each patient and adding it to all dates in the patient diagnoses, laboratory and medication records. This approach maintained differential data analysis per patient. Diagnoses codes were acquired from both primary care and hospitalization records, and were mapped to the ICD-9 coding system for historical reasons, with few exceptions that used a partial ICD-10 coding system. Laboratory records were normalized for age and gender by subtracting raw test values from the median levels observed among all test values with matching gender and age (using a bin size of five years). We observed some chronological biases in laboratory ranges, but avoid normalizing these and instead insured case and controls are matched for chronological distributions. Defining AML cases. We screened for all active patients (18 < age < 100) who were diagnosed with AML (ICD-9 code 205.0*) between the years 2003 and 2016. We then excluded cases based on the following criteria. (1) We excluded patients with prior myeloid malignancies to omit secondary AML, consistent with the case selection for the genetic model. The following diagnosis were excluded if documented within five years before the diagnosis of AML: essential thrombocythemia (ICD-9 238.71), low-grade myelodysplastic syndrome (MDS) (ICD-9 238.72); high-grade MDS lesions (ICD-9 238.73); MDS with 5q deletion (ICD-9 238.74); MDS, unspecified (ICD-9 238.75); polycythemia vera (ICD-9 238.4); myelofibrosis (ICD-9 289.83); chronic myelomonocytic leukaemia (ICD-9 206. 10-206.22 ).
(2) Patients that had any procedures performed on bone marrow or spleen (ICD-10 code Z41) in the five-year period before first mention of AML diagnosis code in their record. These patients were presumed to have an inaccurate AML diagnosis date or misdiagnosis recorded.
(3) Patients that received medications suggestive of an alternative diagnosis of chronic myeloid leukaemia, lymphoid malignancy or acute promyelocytic leukaemia (APL). At any time before diagnosis: imatinib, dasatinib, anagrelide, hydroxycarbamide, asparaginase, pegaspargase or arsenic trioxide. At any time after diagnosis: imatinib, dasatinib, methotrexate, tretinoin or arsenic trioxide. At any time after diagnosis, along with any acute lymphoblastic leukaemia diagnosis (ICD-9 204) or more than single dose: mercaptopurine. APL cases were excluded as early diagnosis of APL will most probably not change its outcome, as treatment is successful already.
(4) Patients without a hospitalization record within three months before or after the onset diagnosis. This parameter was used as it is unlikely that a patient with AML will not be hospitalized close to diagnosis. This filter reduced false-positive cases and better defined the onset date.
We refined the estimated time of onset using the earliest time at which any of the following diagnosis appeared in the patient's history: amyloidosis (ICD-9 277.3), lymphoid leukaemia (ICD-9 204), myeloid leukaemia (ICD-9 205), leukaemia of unspecified cell type (ICD-9 208).
This strategy retained 875 AML cases in the training set for further analysis. These were further validated by manual expert inspection of the complete records of 8% of the cases.
To define the control set, we included all Clalit individuals that were not cases. Since our analysis was aggregating data from a historical time window of 15 years, we associated each control with a randomized time point for evaluation. Using this approach, both cases and controls represented a specific time point in the historical record of a patient, with matching calendric, age and gender distributions. Through this strategy 5,238,528 controls were used. Defining features for construction of a predictive a score. We extracted the following features for discriminative analysis of cases and controls (this procedure was applied repeatedly in cross-validation as discussed below). (1) Age (in years) at time point. (2) Gender. (3) Laboratory features. Out of 2,770 different types of laboratory tests, we selected the top 50 most frequent laboratory tests (Supplementary Table 4 ). For each laboratory measurement, we used median age-and gendernormalized test values per patient in three time windows for 6-12 months before onset, 1-2 years before onset and 2-3 years before onset. In addition, we compute the slope of the normalized laboratory measurements for the 6-12 month time window using a linear regression model. (4) Diagnosis features. Of the 1780 different major ICD-9 diagnosis codes, we selected only diagnoses that were previously observed in at least 10 different cases and have an increased relative risk for AML >twofold (as observed in the training set, Supplementary Table 4 ). For each diagnosis code, we mark whether it appeared in each of the patients in time intervals of 6 months to 3 years, and 3-5 years before onset. (5) BMI features. For each patient in the cohort, we extracted median BMI, weight and height as measured in time intervals of 6 months to 2 years, and 2-3 years before onset. Gradient boosting. We used the R package xgboost to infer parameters for a classifier given cases and controls. Objective was set to binary:logistic, the evaluation metric to AUC. We set nrounds = 5000, eta = 0.001, gamma = 0.1, lambda = 0.01, alpha = 0.01, max_depth = 6, min_child_weight = 2, subsample = 0.7 and col-sample_bytree = 0.7. The boosting algorithm reports a function f that computes a predictive score given the features. Given a threshold T the expression f(patient features) > T defines a classifier. To standardise thresholds we estimate quantiles for the scores on the training set T(p) = quantile(f(train),p) and define the classifier for specificity level p as f(patient features) > T(p) ( Supplementary Table 4 ). Cross-validation and relative risk evaluation. To evaluate the predictive value of the classification scheme while considering the strong age and gender biases in the incidence of AML, we performed fivefold cross-validation after splitting the cases and controls into five age-and gender-matched groups. For each fold, we sampled 100,000 controls and combined with the cases, constructed the feature set and trained the model. The model was then tested on the fold cases along with 200,000 sampled controls. We used standardized classifier parameters and standardized thresholds that were inferred based on each training set to generate a series of classifications on each test set and merged these based on the control quantiles in the test as described above. Given a threshold p to define high and low prediction score, we counted for each bin b that defines a patient in a specific age (<40, 40- Clonal growth rate calculation. Individual clones were defined by different mutations in different study participants. Per clone we calculated α according to the following equation: 
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Extended Data Fig. 4 | AML predictive models. a-c 
Extended Data Fig. 9 | Distribution of EHR model parameters. . As detailed in Methods, we used weighting to minimise the biases introduced by the artificial case-control ratio and calculated hazard ratios relative to the (approximate) true cumulative AML incidence of about 1-3/1,000 in the given age range over a follow up of 10-20 years.
Data exclusions
Describe any data exclusions. For the model described in figure 3 we have excluded samples taken less than 6 months prior AML diagnosis from model training and validation in order to avoid skewing the model towards significance (as per reviewer comments). This resulted in the removal of 4 individuals from the discovery cohort, leaving 91 individuals in the discovery cohort pre-AML group.
Replication
Describe whether the experimental findings were reliably reproduced.
Experimental replication was not attempted but rather validated in a second independent cohort
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
AML patients were identified based on the following ICD9 codes: 9861/3 9860/3 9801/3 9866/3 9891/3 9867/3 9874/3 9840/3 9872/3 9895/3 9873/3, which included only cases of de novo AML, and no secondary AML. Age and gender matched individuals that were not diagnosed for any hematological disorders during the average follow-up period of 12.6 were selected as the control group,
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
For assessment of statistical significant differences between the cases as controls blinding is impractical as the groups must be defined. Machine learning algorithms were blind in a sense as they been configure to be trained and tested in different set of samples.
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Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
Software
Policy information about availability of computer code
Describe the software used to analyze the data in this study.
1) Sequencing reads were aligned using BWA-aln and BWA-mem 2) indel-realignment was done using GATK 2) Variant calling was done using deepSNV, Varscan2, Pindel v2.2 and CaVEMan v1.11.2. All of these algorithms are extensively described and validated in the published literature.
3) Code used to generate predictive models will be deposited on GitHub at the time of manuscript publication For full description please refer to the appropriate method sections For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for providing algorithms and software for publication provides further information on this topic.
Materials and reagents
Policy information about availability of materials
Materials availability
Indicate whether there are restrictions on availability of unique materials or if these materials are only available for distribution by a for-profit company.
No unique material were used in this study
Antibodies
Describe the antibodies used and how they were validated for use in the system under study (i.e. assay and species).
No antibodies were used in this study 10 . No cell lines were used in this study
